David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

2024 ASCO Annual Meeting


David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I am very happy to share with you the interim results from our study of the outpatient administration of Epcoritamab for relapsed and refractory diffused large cell and follicular lymphoma. Epcoritamab as you know is a bispecific antibody for the treatment of B-cell lymphomas. It's currently FDA approved for the treatment of relapsed and refractory diffused large cell lymphoma. One of the major clinical challenges of the use of bispecific antibodies in this space is the phenomenon of the cytokine release syndrome, which is a major toxicity, and as a result, the labels for Epcoritamab and other bispecifics require hospitalization during their first full dose in order to monitor patients for cytokine release syndrome or CRS. This is a major barrier to care. It's often difficult to coordinate with a hospital if the patient's oncologist is not practicing at that hospital or not directly an employee of that hospital. And it also adds cost and inconvenience for the patients. So in this study, we sought to demonstrate the feasibility of outpatient administration exclusively. So patients were recruited who had diffused large B cell lymphoma in the second line and beyond for therapy and follicular lymphoma, the third line and beyond. All patients were educated on CRS and given a wild card with instructions and symptoms to look for. They were instructed to take their temperature three times a day after cycle one day 15, which is the first full dose, and it's known that most of the cytokine release syndrome occurs after that dose. They were required to stay within 30 minutes of the treating institution in case they needed medical help. In addition, patients were pre-medicated with steroids to mitigate the CRS. The report we have this year at ASCO includes 31 patients, and the CRS that we observed was very similar to what was observed in the previous studies. About 25% grade one and 25% grade two after cycle one day 15. Most notably 21 out of 31 patients on the study so far were treated entirely in outpatient setting and were not admitted for any reason. The patients that were admitted, the vast majority were admitted for management of CRS. Most CRS surveillance resolved within 24 to 48 hours, and no patients needed to discontinue from the study because of CRS. Again, in conclusion, we believe this study in the preliminary results demonstrates the feasibility of outpatient administration of Epcoritamab with reflexive rather than preemptive hospitalization. We believe this will expand access to the medication, make it easier for clinicians and patients to obtain, and we hope to present further results including efficacy at a future date.

Related Videos


Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).

Skin Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).